Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind safety and immunogenicity trial of subcutaneous dasiglucagon vs GlucaGen in type 1 diabetes mellitus
2017-000062-30Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dasiglucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Zealand Pharma. Primary endpoint: Overall ADA incidence. Started Feb 2017; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-000062-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000062-30.